Mortality following a cardiovascular or renal event in patients with type 2 diabetes in the ALTITUDE trial
Journal article
Jhund, Pardeep S., McMurray, John J. V., Chaturvedi, Nish, Brunel, Patrick, Desai, Akshay S., Finn, Peter V., Haffner, Steven M., Solomon, Scott D., Weinrauch, Larry A., Claggett, Brian L. and Pfeffer, Marc A.. (2015). Mortality following a cardiovascular or renal event in patients with type 2 diabetes in the ALTITUDE trial. European Heart Journal. 36(36), pp. 2463 - 2469. https://doi.org/10.1093/eurheartj/ehv295
Authors | Jhund, Pardeep S., McMurray, John J. V., Chaturvedi, Nish, Brunel, Patrick, Desai, Akshay S., Finn, Peter V., Haffner, Steven M., Solomon, Scott D., Weinrauch, Larry A., Claggett, Brian L. and Pfeffer, Marc A. |
---|---|
Abstract | Aims: Patients with type 2 diabetes mellitus (T2DM) are at high risk of developing cardiovascular (CV) and renal disease. We examined the burden of, and risk of death following, CV and renal events in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE), a randomized trial of alikiren vs. placebo. Methods and results: We followed 8561 patients with T2DM and evidence of chronic kidney disease, CV disease, or both in ALTITUDE until the first non-fatal CV or renal event of myocardial infarction (MI), stroke, heart failure (HF), and end-stage renal disease (ESRD; initiation of dialysis, renal transplantation, or a serum creatinine concentration above 6.0 mg/dL) and then to death or censoring. Time-updated multivariable Cox models were used to estimate the relative risk of death following each event. In total 1008 patients (12%) experienced at least one first non-fatal CV or renal event (4.1% HF, 2.8% MI, 2.8% stroke, and 2.2% ESRD). Death occurred subsequently in 26.4% of those experiencing a first HF event, 29.7% of those experiencing an MI event, 23.7% of those experiencing a stroke, and 14.7% of those experiencing ESRD, and in 6.5% (488) of the 7553 patients (88%) who did not experience a non-fatal CV or renal event. Compared with patients who did not experience a non-fatal event, the adjusted hazard ratio for death was 5.9 (95% confidence interval 4.6–7.6) after HF, 9.7 (7.5–12.6) after MI, 7.1 (5.3–9.5) after stroke, and 5.8 (3.7–9.0) after ESRD. Conclusion: The majority of deaths occurred in patients who did not experience a non-fatal CV or renal event, although the risk of death was higher following an event. Our findings illustrate continuing opportunities to reduce morbidity and mortality in patients with type 2 diabetes. |
Keywords | diabetes; heart failure; myocardial infarction; stroke; renal disease; mortality |
Year | 2015 |
Journal | European Heart Journal |
Journal citation | 36 (36), pp. 2463 - 2469 |
Publisher | Oxford University Press |
ISSN | 0195-668X |
Digital Object Identifier (DOI) | https://doi.org/10.1093/eurheartj/ehv295 |
Scopus EID | 2-s2.0-84942163799 |
Page range | 2463 - 2469 |
Research Group | Mary MacKillop Institute for Health Research |
Publisher's version | File Access Level Controlled |
Place of publication | United Kingdom |
https://acuresearchbank.acu.edu.au/item/89745/mortality-following-a-cardiovascular-or-renal-event-in-patients-with-type-2-diabetes-in-the-altitude-trial
Restricted files
Publisher's version
99
total views0
total downloads2
views this month0
downloads this month